BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23277474)

  • 1. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
    Terrenoire C; Wang K; Tung KW; Chung WK; Pass RH; Lu JT; Jean JC; Omari A; Sampson KJ; Kotton DN; Keller G; Kass RS
    J Gen Physiol; 2013 Jan; 141(1):61-72. PubMed ID: 23277474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response.
    Bankston JR; Yue M; Chung W; Spyres M; Pass RH; Silver E; Sampson KJ; Kass RS
    PLoS One; 2007 Dec; 2(12):e1258. PubMed ID: 18060054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On optimizing therapies, Orai, and ORNs.
    Adler EM
    J Gen Physiol; 2013 Feb; 141(2):149-50. PubMed ID: 23359279
    [No Abstract]   [Full Text] [Related]  

  • 4. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
    Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R
    Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
    Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
    Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
    Priori SG; Cantù F; Schwartz PJ
    Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
    Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
    PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the long QT syndrome with induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Zwi-Dantsis L; Caspi O; Winterstern A; Feldman O; Gepstein A; Arbel G; Hammerman H; Boulos M; Gepstein L
    Nature; 2011 Mar; 471(7337):225-9. PubMed ID: 21240260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of long QT syndrome with triple gene abnormalities: digenic mutations in KCNH2 and SCN5A and gene variant in KCNE1.
    Yoshikane Y; Yoshinaga M; Hamamoto K; Hirose S
    Heart Rhythm; 2013 Apr; 10(4):600-3. PubMed ID: 23237912
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes.
    Portero V; Casini S; Hoekstra M; Verkerk AO; Mengarelli I; Belardinelli L; Rajamani S; Wilde AAM; Bezzina CR; Veldkamp MW; Remme CA
    Cardiovasc Res; 2017 Jun; 113(7):829-838. PubMed ID: 28430892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
    Bellin M; Casini S; Davis RP; D'Aniello C; Haas J; Ward-van Oostwaard D; Tertoolen LG; Jung CB; Elliott DA; Welling A; Laugwitz KL; Moretti A; Mummery CL
    EMBO J; 2013 Dec; 32(24):3161-75. PubMed ID: 24213244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.
    Kim HJ; Kim BG; Park JE; Ki CS; Huh J; Youm JB; Kang JS; Cho H
    Sci Rep; 2019 Sep; 9(1):12997. PubMed ID: 31506521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
    Abriel H; Wehrens XH; Benhorin J; Kerem B; Kass RS
    Circulation; 2000 Aug; 102(8):921-5. PubMed ID: 10952963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
    Liu H; Tateyama M; Clancy CE; Abriel H; Kass RS
    J Gen Physiol; 2002 Jul; 120(1):39-51. PubMed ID: 12084774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.
    Wang DW; Crotti L; Shimizu W; Pedrazzini M; Cantu F; De Filippo P; Kishiki K; Miyazaki A; Ikeda T; Schwartz PJ; George AL
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):370-8. PubMed ID: 19808432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant.
    Lin MT; Wu MH; Chang CC; Chiu SN; Thériault O; Huang H; Christé G; Ficker E; Chahine M
    Heart Rhythm; 2008 Nov; 5(11):1567-74. PubMed ID: 18848812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome.
    Jouni M; Si-Tayeb K; Es-Salah-Lamoureux Z; Latypova X; Champon B; Caillaud A; Rungoat A; Charpentier F; Loussouarn G; Baró I; Zibara K; Lemarchand P; Gaborit N
    J Am Heart Assoc; 2015 Sep; 4(9):e002159. PubMed ID: 26330336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
    Zhu W; Mazzanti A; Voelker TL; Hou P; Moreno JD; Angsutararux P; Naegle KM; Priori SG; Silva JR
    Circ Res; 2019 Feb; 124(4):539-552. PubMed ID: 30566038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
    Benito B; Brugada R; Perich RM; Lizotte E; Cinca J; Mont L; Berruezo A; Tolosana JM; Freixa X; Brugada P; Brugada J
    Heart Rhythm; 2008 Oct; 5(10):1434-40. PubMed ID: 18929331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.